The global anti-vegf therapeutics market size was valued at USD 14.8 billion in 2025 and is projected to grow from USD 15.14 billion in 2026 to USD 18.19 billion by 2034, registering a CAGR of 2.32% during the forecast period from 2026 to 2034. North America dominated the anti-vegf therapeutics market with a market share of 42.5% in 2025.
Anti-VEGF therapeutics are medicines designed to block vascular endothelial growth factor (VEGF), a protein that promotes the formation and growth of blood vessels. They are widely used to treat conditions such as cancer and retinal diseases by limiting abnormal blood vessel growth. Demand is growing due to increasing cases of cancer and vision disorders, advances in targeted therapies, and rising adoption of biologic treatments.
Download a Free Sample To learn more about this report,
Increasing Adoption of Longer-Acting Anti-VEGF Therapies
The anti-VEGF therapeutics market is increasingly focused on treatments designed to extend dosing intervals and reduce the frequency of intravitreal injections. Longer-acting therapies can help reduce the treatment burden associated with chronic retinal diseases while supporting sustained disease management. Pharmaceutical companies are therefore continuing to develop formulations and delivery approaches intended to provide longer-lasting therapeutic effects.
In February 2025, pharmaceutical companies continued advancing longer-duration treatment approaches for retinal diseases requiring ongoing anti-VEGF therapy.
Growing Development of Biosimilars in Ophthalmology
The availability and development of biosimilar anti-VEGF therapies are becoming increasingly important within the ophthalmology market. Biosimilars can increase treatment options and potentially improve access by introducing additional competition into established therapeutic categories. Their growing presence is contributing to changes in pricing strategies and competitive dynamics among manufacturers of retinal disease treatments.
In August 2025, continued development and commercialization activities involving ophthalmic biosimilars supported greater competition within the retinal therapeutics landscape.
Rising Prevalence of Retinal and Vision-Threatening Diseases
The increasing burden of conditions such as age-related macular degeneration, diabetic macular edema, and other retinal vascular diseases is supporting demand for anti-VEGF therapeutics. Aging populations and the growing prevalence of diabetes are contributing to the number of patients requiring diagnosis and long-term retinal disease management. This expanding patient population provides a fundamental driver for anti-VEGF treatment demand.
In April 2025, healthcare organizations continued emphasizing the growing burden of age-related and diabetes-associated eye diseases requiring effective diagnosis and long-term management.
High Treatment Costs and Financial Burden of Long-Term Therapy
Anti-VEGF treatment can involve substantial costs because many retinal diseases require repeated administration and ongoing clinical monitoring. The cumulative financial burden can create access challenges for patients and healthcare systems, particularly where reimbursement coverage is limited. High treatment costs therefore remain a significant factor affecting the accessibility of certain branded anti-VEGF therapies.
In June 2025, healthcare providers and payers continued managing the financial challenges associated with providing long-term treatment for chronic retinal diseases.
Expansion of Anti-VEGF Treatment Access in Emerging Healthcare Markets
Growing investment in ophthalmology infrastructure and specialized eye-care services creates opportunities for expanding access to anti-VEGF therapeutics in emerging markets. Improvements in diagnostic capabilities, retinal clinics, and healthcare professional training can enable more patients to receive treatment for vision-threatening diseases. The expansion of specialized eye-care capacity therefore represents an important growth opportunity.
In September 2025, healthcare development initiatives continued supporting the expansion of specialized ophthalmology and retinal care capabilities in developing healthcare markets.
Maintaining Patient Adherence to Repeated Treatment and Monitoring
Many anti-VEGF therapies require patients to attend regular clinical appointments for injections and disease monitoring. Frequent visits can create logistical, financial, and physical challenges, particularly for elderly patients and those living far from specialized eye-care facilities. Maintaining long-term adherence to treatment schedules remains a significant challenge for healthcare providers and the anti-VEGF therapeutics market.
In November 2025, retinal care programs continued emphasizing the importance of regular treatment and monitoring to support long-term management of chronic vision-threatening diseases.
Eylea Segment Dominated the Market with 39.8% Share in 2025
The Eylea segment dominated the global anti-VEGF therapeutics market with a 39.8% share in 2025. Eylea is widely used for the treatment of several retinal disorders, including age-related macular degeneration and diabetic eye diseases. Its established clinical use and broad therapeutic applications continue to support the segment's leading position.
Lucentis accounted for 23.4% of the market, followed by Vabysmo with 17.6%. Beovu represented 8.7%, while other products accounted for 10.5%. Vabysmo is growing at the highest CAGR of 13.2%, supported by increasing adoption of newer anti-VEGF treatment options and demand for advanced therapies. These developments are supporting anti-VEGF therapeutics market growth.
Request Customizationto receive a tailored report.
Age-related Macular Degeneration Segment Dominated the Market with 38.7% Share in 2025
The age-related macular degeneration segment dominated the global anti-VEGF therapeutics market with a 38.7% share in 2025. Age-related macular degeneration is a major retinal condition requiring ongoing treatment, creating substantial demand for anti-VEGF therapies. The large patient population and continued need for disease management support the segment's leading position.
Macular edema accounted for 22.6% of the market, followed by diabetic retinopathy at 19.4% and retinal vein occlusion at 14.8%. Diabetic retinopathy is growing at the highest CAGR of 9.1%, driven by the increasing prevalence of diabetes and the resulting risk of retinal complications. Myopic choroidal neovascularization accounted for 4.5% of the market, while continued advances in retinal disease treatment are supporting overall anti-VEGF therapeutics market demand.
Speak to an Analystto discuss market opportunities.
North America dominated the anti-VEGF therapeutics market with a 42.5% share in 2025, valued at USD 6.29 billion, and is projected to grow at a CAGR of 7.2% during the forecast period. The region's advanced healthcare infrastructure, high prevalence of retinal disorders and cancer, strong adoption of biologic therapies, and significant healthcare expenditure are supporting market growth. Increasing demand for targeted therapies, expanding ophthalmology applications, and continued research and development in anti-VEGF treatments are further contributing to regional expansion.
The United States market was valued at approximately USD 5.35 billion in 2025, making it the largest contributor to the North American market. High healthcare expenditure, advanced ophthalmic care infrastructure, increasing prevalence of age-related macular degeneration and diabetic retinopathy, and widespread adoption of anti-VEGF therapies are supporting market development.
The Canada market reached approximately USD 0.94 billion in 2025. Increasing prevalence of retinal diseases, improving access to advanced ophthalmic treatments, rising healthcare expenditure, and growing adoption of biologic therapies are supporting the demand for anti-VEGF therapeutics.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.3% of the global anti-VEGF therapeutics market in 2025, reaching USD 4.04 billion, and is expected to grow at a CAGR of 6.8% during the forecast period. Growing prevalence of ophthalmic disorders, increasing geriatric populations, established healthcare systems, and rising adoption of advanced biologic therapies are driving regional demand. Improvements in diagnosis and treatment of retinal diseases are also supporting the use of anti-VEGF therapeutics.
Germany's market accounted for approximately USD 1.15 billion in 2025. A well-developed healthcare infrastructure, increasing prevalence of age-related retinal disorders, strong adoption of advanced ophthalmic therapies, and growing demand for effective biologic treatments are supporting market growth.
The United Kingdom market reached approximately USD 0.75 billion in 2025. Increasing incidence of retinal diseases, an aging population, established ophthalmology services, and growing adoption of innovative anti-VEGF therapies are contributing to market expansion.
Asia-Pacific accounted for 21.4% of the global anti-VEGF therapeutics market, reaching USD 3.17 billion in 2025, and is projected to grow at the fastest regional CAGR of 9.4% during the forecast period. Rising healthcare expenditure, increasing prevalence of diabetes and retinal disorders, improving healthcare infrastructure, and growing access to advanced biologic treatments are supporting regional growth. Expanding pharmaceutical capabilities and increasing awareness of advanced ophthalmic therapies are also creating opportunities for market development.
Japan's market generated approximately USD 0.67 billion in 2025. Advanced healthcare infrastructure, a growing elderly population, high prevalence of age-related retinal conditions, and strong adoption of innovative ophthalmic treatments are supporting demand for anti-VEGF therapeutics.
China's market accounted for approximately USD 1.55 billion in 2025, making it a major contributor within the Asia-Pacific region. Expanding healthcare infrastructure, rising healthcare expenditure, increasing prevalence of diabetes and retinal diseases, and improving access to advanced biologic therapies are supporting market growth.
Latin America accounted for 5.1% of the global anti-VEGF therapeutics market in 2025, reaching USD 0.75 billion, and is projected to grow at a CAGR of 7.9% during the forecast period. Increasing healthcare investment, rising prevalence of diabetes and retinal disorders, improving access to specialized ophthalmic care, and growing awareness of advanced treatment options are supporting regional market development.
Brazil's market was valued at approximately USD 0.75 billion in 2025. Increasing prevalence of retinal disorders, expansion of healthcare services, improving access to ophthalmic treatments, and growing adoption of advanced biologic therapies are supporting market development.
Middle East & Africa accounted for 3.7% of the global anti-VEGF therapeutics market in 2025, reaching USD 0.55 billion, and is expected to grow at a CAGR of 7.1% during the forecast period. Increasing healthcare infrastructure investment, rising prevalence of diabetes-related eye diseases, healthcare modernization, and improving access to specialized treatments are supporting regional growth. Growing awareness of advanced ophthalmic therapies is also contributing to increased adoption.
The UAE market was valued at approximately USD 0.19 billion in 2025. Healthcare infrastructure development, increasing investment in advanced medical technologies, rising prevalence of ophthalmic disorders, and growing access to specialized eye-care services are supporting the adoption of anti-VEGF therapeutics.
The global Anti-VEGF Therapeutics market is highly competitive, driven by the rising prevalence of retinal disorders, increasing demand for targeted therapies, and continued development of treatments for conditions such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Key players include Regeneron Pharmaceuticals, Inc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd., Fresenius Kabi, Biogen, Pfizer, Inc., Alvotech, Teva Pharmaceuticals, Coherus Biosciences, Inc., Amgen, Inc., Bausch Health Companies, Inc., Viatris, Inc., Sanofi, Isarna Therapeutics, Genentech, SamChunDang Pharm, Formycon AG, and Bioeq AG. Companies are focusing on novel biologics, biosimilars, longer-acting therapies, improved drug delivery, and expanded treatment options to strengthen their market position.
Regeneron Pharmaceuticals, Inc.: An Emerging Market Leader
Regeneron has strengthened its position through its ophthalmology portfolio, including anti-VEGF therapies used to treat several retinal diseases. The company focuses on innovative biologic therapies, improved treatment outcomes, and research aimed at addressing a broad range of retinal conditions. These capabilities support Regeneron’s strong position in the global anti-VEGF therapeutics market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com